贝伐珠单抗联合华蟾素片改善肝癌患者腹水的临床观察  

Clinical observation of bevacizumab combined with cinobufacini tablets in improving ascites in patients with liver cancer

作　　者：刘朝敏[1,3] 蒋婷[2] 刘薇[1] 温彪[3] 罗兴 LIU Chaomin;JIANG Ting;LIU Wei(Department of Oncology,First Affiliated Hospital of Chengdu Medical College,Chengdu Sichuan 610500,China;Department of Pharmacy,First Affiliated Hospital of Chengdu Medical College,Chengdu Sichuan 610500,China;Department of Gastroenterology,First Affiliated Hospital of Chengdu Medical College,Chengdu Sichuan 610500,China)

机构地区：[1]成都医学院第一附属医院肿瘤科,四川成都610500 [2]成都医学院第一附属医院消化内科,四川成都610500 [3]成都医学院第一附属医院药学部,四川成都610500

出　　处：《四川中医》2023年第6期129-132,共4页Journal of Sichuan of Traditional Chinese Medicine

基　　金：四川省卫生健康委员会科研课题(普及应用项目)(NO.20PJ155);成都医学院校级教育教学改革研究课题(一般项目)(NO.JG2022022)。

摘　　要：目的:探讨贝伐珠单抗联合华蟾素片治疗肝癌伴腹水患者的临床疗效。方法:选取本院2020年2月~2021年12月收治的96例肝癌伴腹水患者,按随机数字表法分为观察组和对照组,各48例。采取腹腔灌注贝伐珠单抗及顺铂进行治疗,每周用药1次,4周为1个疗程,共2个周期。观察组在对照组基础上于腹腔灌注前1周口服华蟾素片,连续口服至腹腔灌注治疗2个周期结束。比较两组总有效率、生活质量改善情况及毒副反应。结果:观察组腹水治疗的总有效率为79.17%,高于对照组58.33%(P<0.05)。观察组治疗后的生活质量改善率为68.75%,高于对照组47.92%,差异有统计学意义(P<0.05)。两组治疗期间未出现Ⅲ、Ⅳ度毒副反应,患者耐受情况良好。两组白细胞减少、血小板减少、血红蛋白减少等毒副反应总发生率的比较,差异无统计学意义(P>0.05)。结论:贝伐珠单抗联合华蟾素片治疗肝癌伴腹水患者可通过抑制肿瘤浸润与癌性渗出有效改善腹水,促进患者生活质量的提高,患者耐受良好,值得推广。Objective To investigate the clinical efficacy of bevacizumab combined with cinobufacin tablets in the treatment of patients with liver cancer and ascites.Methods A total of 96patients with liver cancer and ascites who were admitted to our hospital from February 2020to December 2021were selected and divided into an observation group and a control group according to the ran-dom number table method,with 48cases in each.The control group was treated with intraperitoneal infusion of bevacizumab and fluorouracil,once a week,for 4weeks as a course of treatment,for a total of 2cycles.On the basis of the control group,the observation group was treated with cinobufacin tablets were orally administered Iweek before the intraperitoneal infusion,and the oral administration continued until the end of the 2cycles of intraperitoneal infusion.The total effective rate,life quality improvement,toxic side effects were compared between the two groups.Results:The total effective rate of ascites treatment in the observation group was 79.17%,which was higher than 58.33%in the control group(P<0.05).The improvement rate of the quality of life in the observation group after treatment was 68.75%,which was higher than that in the control group,which was 47.92%,and the difference was statistically significant(P<0.05).During the treatment period,there were no toxic side effects of grade II and IV in the two groups,and the patients tolerated them well.There were no significant difference in the total incidence of leukopenia,thrombocytopenia,and hemoglobin reduction between the two groups(P>0.05).Conclusion Bevacizumab combined with cinobufacini tablets in the treatment of patients with liver cancer and ascites can effectively improve ascites by inhibiting tumor infiltration and cancerous exudation,and promote the improvement of patients'quality of life.The patients are well tolerated and worthy of promotion.

关 键 词：肝癌 腹水 贝伐珠单抗 华蟾素片 生活质量 

分 类 号：R735.7[医药卫生—肿瘤]